1. An isolated monoclonal antibody (mAb) or immunoreactive fragment thereof that: (a) bind epitope AD2 protein gB strain AD169 cytomegalovirus (CMV) with an affinity of at least 10nM (b) is a human antibody or fragment thereof, and ( c) neutralize CMV in culture fibroblast kletok.2. mAb of claim 1 which is in the form of full antibodies or bispecific antitela.3. mAb or fragment of claim 1 or 2, which have affinity for an epitope AD2 gB strain AD169 CMV at least 1 nM.4. The antibody of claim 1, gdea) has a heavy chain CDR1 GFTFNRHG (SEQ ID NO: 67) and the region CDR2 SSDGANQ (SEQ ID NO: 69), and the region CDR3 ARDGRCEGERCYSGVTDF (SEQ ID NO: 71), or b) has a heavy chain CDR1 GSISSEDFC (SEQ ID NO: 68) and the region CDR2 ICYTGD (SEQ ID NO: 70), and the region CDR3 AREDRRQLHSRPYFYYGLDV (SEQ ID NO: 72), or c) has a heavy chain CDR1 DYNMH (position 31-35 SEQ ID NO: 22) and the region CDR2 VISIDGTYKYSADSVAG (position 50-66 SEQ ID NO: 22), and the region CDR3 DGRSVGGFSGILD (positions 99-111 SEQ ID NO: 22) .5. The antibody of claim 4, wherein the light chain according to a) has a region CDR1 QNIGGY (SEQ ID NO: 73) and the region CDR2 DAS (SEQ ID NO: 75), and the region CDR3 QQRNSWPPLT (SEQ ID NO: 77), the chain according ililegkaya b) has a region CDR1 QSLLHSNGHNY (SEQ ID NO: 74) and the region CDR2 LG (SEQ ID NO: 76) and the region CDR3 QALQTPNT (SEQ ID NO: 78), ililegkaya circuit according to c) has a region CDR1 RASQSVGSYLA (position 24-34 SEQ ID NO: 36) and the region CDR2 DSSVRAT (position 50-56 SEQ ID NO: 36) and the region CDR3 QQRNNWPPLT (position 89-98 SEQ ID NO: 36) .6. The antibody or fragment of claim 1, which represent 4A2, 19B10, 313, 338 or 345.7. The antibody or fragment according to claim 6, which represent 4A2, having a light chain variable region SEQ ID NO: 4 and the sequence of the variable region of the heavy chain of SEQ ID NO: 2, or which represent 345 having a light chain variable region SEQ ID NO: 36 and the sequence of the variable region of SEQ ID
